Spondyloarthritis & psoriatic arthritis
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
Authors' conclusion
Fewer AEs were observed over 3 years for younger versus older patients with PsA. There were no clinically meaningful treatment response differences. Persistence was numerically higher in the older age group.
Study context
- Population
- Patients with PsA receiving ustekinumab in the PsABio real-world study, over 3 yearssimilar gender balance
- Participants
- 336 vs 103
- Comparison
- Patients <60 vs ≥60 years receiving ustekinumab
- <60 YEARSn = 336
- ≥60 YEARSn = 103reference
Methodological detailsdescriptive analysis
- Descriptive analysis
Primary result
As reported in the abstract
cDAPSA low disease activity (LDA) including remission · 6 months
Further findings
Stopped or switched treatment (persistence)
| Outcome | <60 YEARS | ≥60 YEARS |
|---|---|---|
| PsAID-12 mean score · 6 months | 3.81 | 3.88 |
| Baseline mean | 5.73 | 5.61 |
| PsAID-12 mean score · 36 months | 2.02 | 3.24 |
- Stopped or switched treatment (persistence): 173/336 vs 47/103
Safety
At least one AE
- At least one adverse events (AE): 124/379 vs 47/115
Serious AEs
- Low in both groups
- < 10%
Original publication
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. Arthritis Res Ther. Published 9 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →